Frequency News and Research

RSS

Acupuncture treatments may help alleviate side effects of breast cancer drugs

A new analysis has found that both real and sham acupuncture treatments may help alleviate side effects of drugs commonly used to treat breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help clinicians improve care for cancer patients. The results also raise the question of whether sham acupuncture is truly inert or may, like real acupuncture, have beneficial effects.

24 Dec 2013

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Breast cancer patients experience fewer side effects while being treated with a widely used drug called an aromatase inhibitor when they get acupuncture - either the real treatment or a "sham" procedure, according to a new study led by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

23 Dec 2013

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Both real and sham weekly acupuncture treatments eased hot flashes and other side effects of anticancer drug treatment in a small, preliminary study of breast cancer patients, Baltimore researchers have found.

23 Dec 2013

Inflammatory burden increased in overweight bipolar disorder patients

Breakdown of the amino acid tryptophan is increased in euthymic, overweight individuals with bipolar disorder, show preliminary results from the BIPFAT study.

20 Dec 2013

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested.

20 Dec 2013

USC's Keck Medicine becomes world's first center to implant responsive brain device to treat epilepsy

On Dec. 18, Keck Medicine of USC became the world's first medical center to implant a responsive brain device newly approved by the Food and Drug Administration to treat epilepsy, with potential to help millions of people worldwide.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Study finds 87% of teens who quit chewing gum experience relief of migraine headache

Teenagers are notorious for chewing a lot of gum. The lip smacking, bubble popping, discarded gum stuck to the sole give teachers and parents a headache.

20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

Restraint, seclusion in schools are used more frequently on students with disability

The restraint and seclusion of students in U.S. public schools in response to student behavior problems are used much more frequently on students with a disability than on students without a disability, and especially in affluent school districts, according to new research at the Carsey Institute at the University of New Hampshire.

18 Dec 2013

Studies offer new insight into diverticulosis

Diverticulosis, a condition that develops when pouches form in the wall of the colon, is increasing in frequency. It affects the majority of those reaching the age of 80 - a growing portion of the population - and imposes a substantial burden on health-care resources, but curiously there is a lack of data and unanswered questions around this condition.

18 Dec 2013

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.

17 Dec 2013

New report shows death rates for lung cancer dropping at a faster pace

The Annual Report to the Nation on the Status of Cancer, covering the period 1975, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years. The recent larger drop in lung cancer deaths is likely the result of decreased cigarette smoking prevalence over many years, and is now being reflected in mortality trends. The lung cancer death rate decline, as well as declines in colorectal, breast, and prostate cancer death rates, has also helped drive decreases in death rates for all cancers types combined, a trend that began about 20 years ago.

17 Dec 2013

Research on neurofeedback training proves to improve attention, working memory performance

The Distinguished Professor Shu-Lan Hsieh's research on neurofeedback training has proven to improve attention and working memory performance, National Cheng Kung University revealed recently.

17 Dec 2013

U-M researchers report novel approach for treating tinnitus in humans

For tens of millions of Americans, there's no such thing as the sound of silence. Instead, even in a quiet room, they hear a constant ringing, buzzing, hissing, humming or other noise in their ears that isn't real. Called tinnitus, it can be debilitating and life-altering.

17 Dec 2013

Data show that HCV genotype-1 infected patients may benefit from faldaprevir

Data show that Boehringer Ingelheim’s second-generation protease inhibitor faldaprevir, when used in combination with pegylated interferon and ribavirin, was effective even with the presence of naturally-occurring mutant variants of the hepatitis C virus, such as the NS3 Q80K polymorphism

16 Dec 2013

Research roundup: Long-term care use varies dramatically by state; health spending slowdown explained

In 2012, about 58,500 paid, regulated long-term care services providers served about 8 million people in the United States. Long-term care services were provided by 4,800 adult day services centers, 12,200 home health agencies, 3,700 hospices, 15,700 nursing homes, and 22,200 assisted living and similar residential care communities. Each day in 2012, there were 273,200 participants enrolled in adult day services centers, 1,383,700 residents in nursing homes, and 713,300 residents in residential care communities; in 2011, about 4,742,500 patients received services from home health agencies, and 1,244,500 patients received services from hospices. Provider sectors differed in ownership, and average size and supply varied by region (Harris-Kojetin et al., 12/12).

16 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Indegene’s MCM division launches Brand-Focused Solutions for brand marketing teams

Indegene, a leading provider of R&D, commercial, and marketing solutions to top global pharmaceutical and healthcare organizations, today announced that its Multi-channel Marketing (MCM) division has launched a suite of Brand-Focused Solutions for the brand marketing teams.

13 Dec 2013

Cardiac patients can benefit from home-based high intensity training

Cardiac patients can benefit from home-based high intensity training, even without the support of fancy training equipment or a clinic, new research from the Norwegian University of Science and Technology has shown.

13 Dec 2013

Frequency News and Research

Acupuncture treatments may help alleviate side effects of breast cancer drugs

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Inflammatory burden increased in overweight bipolar disorder patients

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

USC's Keck Medicine becomes world's first center to implant responsive brain device to treat epilepsy

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Study finds 87% of teens who quit chewing gum experience relief of migraine headache

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Restraint, seclusion in schools are used more frequently on students with disability

Studies offer new insight into diverticulosis

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

New report shows death rates for lung cancer dropping at a faster pace

Research on neurofeedback training proves to improve attention, working memory performance

U-M researchers report novel approach for treating tinnitus in humans

Data show that HCV genotype-1 infected patients may benefit from faldaprevir

Research roundup: Long-term care use varies dramatically by state; health spending slowdown explained

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Indegene’s MCM division launches Brand-Focused Solutions for brand marketing teams

Cardiac patients can benefit from home-based high intensity training

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News